ExonHit Therapeutics which may be contained herein are for illustrative
purposes only and are based on management's current views and assumptions.
Such projections, forecast and estimates involve known and unknown risks
and uncertainties, as described at Section 4.2 "Facteurs de risque" (Risk
Factors) of the Document de Base available on ExonHit Therapeutics' website
), that may cause actual results, performance or
events to differ materially from those anticipated in the summary
In addition, ExonHit Therapeutics, its shareholders, and its
affiliates, directors, officers, advisors and employees have not verified
the accuracy of, and make no representations or warranties in relation to,
statistical data or predictions contained in this press release that were
taken or derived from third party sources or industry publications, and
such statistical data and predictions are used in this press release for
information purposes only.
Finally, this press release may be drafted in the French and English
languages. In an event of differences between the texts, the French
language version shall prevail.
Bruno Tocque, C.E.O.
Philippe Rousseau, C.F.O.
Page: 1 2 3 Related biology technology :1
|SOURCE ExonHit Therapeutics SA|
Copyright©2007 PR Newswire.
All rights reserved
. The Genesis of Gendicine: The Story Behind the First Gene Therapy2
. Midwest life science stocks sizzle in a tepid first quarter3
. Morgridge Institute for Research seeks first CEO4
. Sonic Foundry reports first cash-positive quarter5
. Angel investors commit $12.7B in first half of `066
. Aurora team implants Wisconsins first total artificial heart7
. First half of 2006 roundup: Big Pharma trumps biotech8
. GE announces first installation of Discovery VCT9
. GE Healthcare enjoys robust growth in first quarter10
. Madison asks for wireless bids; airport, downtown would be first11
. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx